2022 World Conference on Lung Cancer (ePosters)-EP08.04-003. A Simple Clinical Prediction Score to Determine Response to First Line Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

EP08.04-003. A Simple Clinical Prediction Score to Determine Response to First Line Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

Back to course

Pdf Summary

Researchers have developed a clinical prediction score (CPS) to determine the response to first-line chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. The study included 207 patients with unresectable stage IIIB or IV NSCLC who received platinum-doublets chemotherapy at Surin Hospital Cancer Center between July 2014 and December 2018. The CPS was based on six clinical parameters: gender, age, smoking status, ECOG score, pretreatment albumin, and histologic subtype. The CPS ranged from 0-13, with a score of 0-8 indicating a low probability of chemotherapy response and a score of 8.5-13 indicating a high probability of response. The predictive model had an area under the receiver operating characteristic curve (AuROC) of 0.71. Internal validation using the bootstrap technique confirmed the consistency of the model with an AuROC of 0.66. <br /><br />The study suggests that NSCLC patients with a high CPS of 8.5-13 have a higher probability of responding to first-line chemotherapy. This information can be useful for physicians in patient selection and for communication with patients and their families regarding the risk-benefit analysis of using cytotoxic agents. The outcomes of advanced NSCLC patients have improved with novel therapies such as tyrosine kinase inhibitors and immune checkpoint inhibitors. However, in countries with limited resources, platinum-doublets chemotherapy is commonly used as the first-line regimen. The CPS can help guide treatment decisions and improve patient outcomes in these settings. <br /><br />The study was supported by Surin Hospital Cancer Center, Surin Medical Education Center, and Chiangmai University. The authors reference several studies and acknowledge the limitations of their research. Overall, the CPS shows promise as a tool for predicting response to first-line chemotherapy in advanced NSCLC patients.

Asset Subtitle

Chawalit Chayangsu

Meta Tag

Speaker Chawalit Chayangsu

Topic Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy

Keywords

clinical prediction score

first-line chemotherapy

advanced non-small cell lung cancer

NSCLC patients

platinum-doublets chemotherapy

chemotherapy response

predictive model

patient selection

tyrosine kinase inhibitors

immune checkpoint inhibitors